Periodontal (gums) diseases include infections of gums and its surrounding tissue which causes loosening of teeth. There are two forms of periodontal diseases which include gingivitis and periodontitis. Gingivitis is inflammation of gums and usually precedes periodontitis. Timely treatment of gingivitis leads to healthy gums, but if the inflammation is left unnoticed, it may lead to periodontitis causing an irreversible damage. Oral health is a growing concern across the globe, where around 45% of the Americans suffered from periodontitis in 2012 according to American Academy of Periodontology. The study also indicated that the prevalence is higher in men (56%) as compared to women.
The periodontal disease therapeutics market is leveraged by the rising prevalence of diabetes which is one of the major predisposing factors for infections in the body including gums. Smoking, hormonal changes are other reasons which lead to gum problems. With rising awareness about oral health and hygiene, the market is expected to grow in Asia-Pacific and other countries in Latin America and the Middle East. Cost of branded drugs is also a barrier for the growth of the market in developing economies. Although currently generic form of Periostat alone is available in the market, patent expiry is expected to fuel the market growth in the near future. Owing to high spending capacities, increased awareness, better reimbursement scenario, Europe and North America lad the market. Major players in the market include OraPharma, Inc., Kaken Pharmaceutical, and Fibrocell Sciences, Inc., DexcelPharma.
Read More: https://bit.ly/3mAAt1M
